Cargando…
SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
Since 2020, the receptor-binding domain (RBD) of the spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been constantly mutating, producing most of the notable missense mutations in the context of “variants of concern”, probably in response to the vaccine-dri...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619214/ https://www.ncbi.nlm.nih.gov/pubmed/34829998 http://dx.doi.org/10.3390/ijms222212114 |
_version_ | 1784604936071282688 |
---|---|
author | Yang, Lin Li, Jiacheng Guo, Shuai Hou, Chengyu Liao, Chenchen Shi, Liping Ma, Xiaoliang Jiang, Shenda Zheng, Bing Fang, Yi Ye, Lin He, Xiaodong |
author_facet | Yang, Lin Li, Jiacheng Guo, Shuai Hou, Chengyu Liao, Chenchen Shi, Liping Ma, Xiaoliang Jiang, Shenda Zheng, Bing Fang, Yi Ye, Lin He, Xiaodong |
author_sort | Yang, Lin |
collection | PubMed |
description | Since 2020, the receptor-binding domain (RBD) of the spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been constantly mutating, producing most of the notable missense mutations in the context of “variants of concern”, probably in response to the vaccine-driven alteration of immune profiles of the human population. The Delta variant, in particular, has become the most prevalent variant of the epidemic, and it is spreading in countries with the highest vaccination rates, causing the world to face the risk of a new wave of the contagion. Understanding the physical mechanism responsible for the mutation-induced changes in the RBD’s binding affinity, its transmissibility, and its capacity to escape vaccine-induced immunity is the “urgent challenge” in the development of preventive measures, vaccines, and therapeutic antibodies against the coronavirus disease 2019 (COVID-19) pandemic. In this study, entropy–enthalpy compensation and the Gibbs free energy change were used to analyze the impact of the RBD mutations on the binding affinity of SARS-CoV-2 variants with the receptor angiotensin converting enzyme 2 (ACE2) and existing antibodies. Through the analysis, we found that the existing mutations have already covered almost all possible detrimental mutations that could result in an increase of transmissibility, and that a possible mutation in amino-acid position 498 of the RBD can potentially enhance its binding affinity. A new calculation method for the binding energies of protein–protein complexes is proposed based on the entropy–enthalpy compensation rule. All known structures of RBD–antibody complexes and the RBD–ACE2 complex comply with the entropy–enthalpy compensation rule in providing the driving force behind the spontaneous protein–protein docking. The variant-induced risk of breakthrough infections in vaccinated people is attributed to the L452R mutation’s reduction of the binding affinity of many antibodies. Mutations reversing the hydrophobic or hydrophilic performance of residues in the spike RBD potentially cause breakthrough infections of coronaviruses due to the changes in geometric complementarity in the entropy–enthalpy compensations between antibodies and the virus at the binding sites. |
format | Online Article Text |
id | pubmed-8619214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86192142021-11-27 SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape Yang, Lin Li, Jiacheng Guo, Shuai Hou, Chengyu Liao, Chenchen Shi, Liping Ma, Xiaoliang Jiang, Shenda Zheng, Bing Fang, Yi Ye, Lin He, Xiaodong Int J Mol Sci Article Since 2020, the receptor-binding domain (RBD) of the spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been constantly mutating, producing most of the notable missense mutations in the context of “variants of concern”, probably in response to the vaccine-driven alteration of immune profiles of the human population. The Delta variant, in particular, has become the most prevalent variant of the epidemic, and it is spreading in countries with the highest vaccination rates, causing the world to face the risk of a new wave of the contagion. Understanding the physical mechanism responsible for the mutation-induced changes in the RBD’s binding affinity, its transmissibility, and its capacity to escape vaccine-induced immunity is the “urgent challenge” in the development of preventive measures, vaccines, and therapeutic antibodies against the coronavirus disease 2019 (COVID-19) pandemic. In this study, entropy–enthalpy compensation and the Gibbs free energy change were used to analyze the impact of the RBD mutations on the binding affinity of SARS-CoV-2 variants with the receptor angiotensin converting enzyme 2 (ACE2) and existing antibodies. Through the analysis, we found that the existing mutations have already covered almost all possible detrimental mutations that could result in an increase of transmissibility, and that a possible mutation in amino-acid position 498 of the RBD can potentially enhance its binding affinity. A new calculation method for the binding energies of protein–protein complexes is proposed based on the entropy–enthalpy compensation rule. All known structures of RBD–antibody complexes and the RBD–ACE2 complex comply with the entropy–enthalpy compensation rule in providing the driving force behind the spontaneous protein–protein docking. The variant-induced risk of breakthrough infections in vaccinated people is attributed to the L452R mutation’s reduction of the binding affinity of many antibodies. Mutations reversing the hydrophobic or hydrophilic performance of residues in the spike RBD potentially cause breakthrough infections of coronaviruses due to the changes in geometric complementarity in the entropy–enthalpy compensations between antibodies and the virus at the binding sites. MDPI 2021-11-09 /pmc/articles/PMC8619214/ /pubmed/34829998 http://dx.doi.org/10.3390/ijms222212114 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yang, Lin Li, Jiacheng Guo, Shuai Hou, Chengyu Liao, Chenchen Shi, Liping Ma, Xiaoliang Jiang, Shenda Zheng, Bing Fang, Yi Ye, Lin He, Xiaodong SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape |
title | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape |
title_full | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape |
title_fullStr | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape |
title_full_unstemmed | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape |
title_short | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape |
title_sort | sars-cov-2 variants, rbd mutations, binding affinity, and antibody escape |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619214/ https://www.ncbi.nlm.nih.gov/pubmed/34829998 http://dx.doi.org/10.3390/ijms222212114 |
work_keys_str_mv | AT yanglin sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT lijiacheng sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT guoshuai sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT houchengyu sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT liaochenchen sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT shiliping sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT maxiaoliang sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT jiangshenda sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT zhengbing sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT fangyi sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT yelin sarscov2variantsrbdmutationsbindingaffinityandantibodyescape AT hexiaodong sarscov2variantsrbdmutationsbindingaffinityandantibodyescape |